{"id":15498,"date":"2021-01-05T01:23:49","date_gmt":"2021-01-04T22:23:49","guid":{"rendered":"https:\/\/www.klimikdergisi.org\/\/2021\/01\/05\/cross-resistance-to-hcv-ns3-inhibitor-developing-during-treatment-with-peginterferon-ribavirin-and-telaprevir\/"},"modified":"2021-01-05T01:23:49","modified_gmt":"2021-01-04T22:23:49","slug":"cross-resistance-to-hcv-ns3-inhibitor-developing-during-treatment-with-peginterferon-ribavirin-and-telaprevir","status":"publish","type":"post","link":"https:\/\/www.klimikdergisi.org\/en\/2021\/01\/05\/cross-resistance-to-hcv-ns3-inhibitor-developing-during-treatment-with-peginterferon-ribavirin-and-telaprevir\/","title":{"rendered":"Cross Resistance to HCV NS3 Inhibitor Developing During Treatment With Peginterferon, Ribavirin and Telaprevir"},"content":{"rendered":"<h1>Abstract<\/h1>\n<p> In this report, a patient with chronic hepatitis C who was null responder to peginterferon and ribavirin and also developed viral rebound in the twelfth week of combination treatment with telaprevir is presented. NS3 resistance analysis performed at the same week has shown sensitivity to paritaprevir but resistance to telaprevir, boceprevir and simeprevir. The resistance analysis may assist the selection of antiviral drugs especially in the chronic hepatitis C patients with virologic failure.<span lang=\"EN-US\">\u00a0\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Abstract In this report, a patient with chronic hepatitis C who was null responder to peginterferon and ribavirin and also developed viral rebound in the twelfth week of combination treatment with telaprevir is presented. NS3 resistance analysis performed at the same week has shown sensitivity to paritaprevir but resistance to telaprevir, boceprevir and simeprevir. The [&hellip;]<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[5132],"tags":[2789,4454,3659,4456],"class_list":["post-15498","post","type-post","status-publish","format-standard","hentry","category-case-report","tag-hepatitis-c-virus","tag-telaprevir","tag-treatment","tag-viral-drug-resistance"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.klimikdergisi.org\/en\/wp-json\/wp\/v2\/posts\/15498","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.klimikdergisi.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.klimikdergisi.org\/en\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.klimikdergisi.org\/en\/wp-json\/wp\/v2\/comments?post=15498"}],"version-history":[{"count":0,"href":"https:\/\/www.klimikdergisi.org\/en\/wp-json\/wp\/v2\/posts\/15498\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.klimikdergisi.org\/en\/wp-json\/wp\/v2\/media?parent=15498"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.klimikdergisi.org\/en\/wp-json\/wp\/v2\/categories?post=15498"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.klimikdergisi.org\/en\/wp-json\/wp\/v2\/tags?post=15498"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}